References
- Preskorn H S. Antidepressant drug selection. J Clin Psychiatry 1994; 55((9, suppl A))6–22
- Hamilton M. A rating scale for depression. J Neural Neurosurg Psychiatry 1960; 23: 56–62
- Healy D, McMonagle T. The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol 1997; 11(Suppl)S25–S31
- Brunello N, Racagni G. Rationale for the development of noradrenaline reuptake inhibitors. Hum Psychopharmacol 1998; 13: S13–S19
- Montgomery S A. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997; 11(Suppl)S9–S15
- Bosc M, Dubini A, Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur Neuropsychopharmacol 1997; 7(Suppl 1)S49–S55
- Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 1997; 11(Suppl)S33–S37
- Dostert P, Benedetti M S, Poggesi I. Review of pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997; 7(Suppl 1)S23–S35
- Healy D. The Antidepressant Era. Harvard University Press, Cambridge, MA 1997
- Wells K B, Stewart A, Hays R D, et al. The functioning and well-being of depressed patients. JAMA 1989; 262: 914–9
- Tweed D L. Depression-related impairment: estimating concurrent and lingering effects. Psychol Med 1993; 23: 373–86
- Versiani M. The selective noradrenaline reuptake inhibitor, reboxetine, has an early onset of action. American Psychiatric Association Meeting, Toronto, June, 1998, Abstract NR678
- Katona C. Reboxetine is as effective and better tolerated than imipramine in elderly patients with depression. American Psychiatric Association Meeting, Toronto, June, 1998, Abstract NR337.
- Stassen H H, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Euro Neuropsychopharmacol 1993; 3: 127–35
- Dubini A, Bosc M, Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 1997; 11(Suppl)S17–23
- Massana J, Moller H J, Burrows G D, et al. Reboxetine: a double blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1998, (in press).
- Schildkraut J J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509–22
- Montgomery S A. Is there a role for a pure noradrenergic drug in the treatment of depression?. Eur Neurophyschopharmacol 1997; 7(Suppl 1)S3–S9
- Carlsson A, Corrodi H, Fuxe K, Hokfelt T. The effects of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-metatyramine. Eur J Pharmacol 1969; 5: 357–66
- Nelson J C, Mazure C M, Bowers M B, Jatlow P I. Drug-responsive symptoms in melancholia. Arch Gen Psychiatry 1984; 41: 663–8